Disclosed are quinoline carboxamide and quinoline carbonitrile compounds of formula (I) wherein ring A, RQ, -L-, R1, n, R2, and R3 are as defined in the specification. The compounds are useful as non-competitive metabotropic glutamate receptor 2 (mGluR2) antagonists, or mGluR2 negative allosteric modulators (NAMs), and in methods of treating diseases or disorders in which the mGluR2-NAM receptor is involved, such as Alzheimer’s disease, cognitive impairment, schizophrenia and other mood disorders, pain disorders and sleep disorders. Examples of a compound of formula (I) are: 4-(4-fluorophenyl)-7-((3-methyl-2,5-dioxoimidazolidin-1-yl)methyl)quinoline-2-carboxamide 7-[(2,5-dioxopyrrolidin-1-yl)methyl]-4-(4-methoxyphenyl)quinoline-2-carboxamide Ethyl-1-{ [2-carbamoyl-4-(4-fluorophenyl)quinolin-7-yl]methyl} -3-(trifluoromethyl)-1H-pyrazole-4-carboxylate 7-[(4,4-dimethyl-2,6-dioxopiperidin-1-yl)methyl]-4-(4-fluorophenyl)quinoline-2-carbonitrile
Quinoline carboxamide and quinoline carbonitrile derivatives as mglur2-negative allosteric modulators, compositions, and their use